A preliminary open study of the tolerability and effectiveness of nefazodone in major depressive disorder: Comparing patients who recently discontinued an SSRI with those on no recent antidepressant treatment

Depression and Anxiety

Volumn 19, Issue 1, 2004, Pages 43-50

  Mischoulon, David ^a,b   Opitz, Gudrun ^a   Kelly, Karen ^a   Fava, Maurizio ^a   Rosenbaum, Jerrold F ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b WAC 812 ^*  (United States)

Author keywords

Antidepressant; Clinical services; Depression; Effectiveness; Nefazodone; SSRI; Tolerability

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; NEFAZODONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HAMILTON SCALE; HEADACHE; HEART PALPITATION; HUMAN; MALE; NAUSEA; PRIORITY JOURNAL; SEDATION; SIDE EFFECT; TREATMENT OUTCOME; URINE RETENTION;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PERSONALITY ASSESSMENT; PERSONALITY INVENTORY; PROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME; TRIAZOLES;

EID: 1542320196     PISSN: 10914269     EISSN: None     Source Type: Journal    
DOI: 10.1002/da.10127     Document Type: Article

References (50)

1. Amsterdam JD, Maislin G, Potter L. 1994. Fluoxetine efficacy in treatment resistant depression. Prog Neuropsychopharmacol Biol Psychiatry 18:243-261.
2. Asnis GM, Wetzler S, Sanderson WC, Kahn RS, van Praag HM. 1992. Functional interrelationship of serotonin and norepinephrine: Cortisol response to MCPP and DMI in patients with panic disorder, patients with depression, and normal control subjects. Psychiatry Res 43:65-76.
3. Baldwin DS, Hawley CJ, Abed RT, Maragakis BP, Cox J, Buckingham SA, Pover GH, Ascher A. 1996. A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression. J Clin Psychiatry 57:46-52.
4. Barbhaiya RH, Buch AB, Greene DS. 1996. Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. Br J Clin Pharmacol 42:573-581.
5. Bech P, Bolwig TG, Kramp P, Rafaelsen OJ. 1979. The Bech-Rafaelsen Mania Scale and the Hamilton Depression Scale. Acta Psychiatr Scand. 59:420-430.
6. Bech P, Shapiro RW, Sihm F, Nielsen BM, Sorensen B, Rafaelsen OJ. 1980. Personality in unipolar and bipolar manic-melancholic patients. Acta Psychiatr Scand 62:245-257.
7. Benazzi F. 1997. Dangerous interaction with nefazodone added to fluoxetine, desipramine, venlafaxine, valproate and clonazepam combination therapy (letter). J Psychopharmacol 11:190-191.
8. Caccia S. 1998. Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications. Clin Pharmacokinet 34:281-302.
9. Charney DS, Woods SW, Goodman WK, Heninger GR. 1987. Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects. Psychopharmacology (Berl) 92:14-24.
10. Dominguez RA, Goodnick PJ. 1995. Adverse events after the abrupt discontinuation of paroxetine. Pharmacotherapy 15:778-780.
11. El-Mallakh RS. 1999. Rapid fade of antidepressant effect of nefazodone in bipolar depression. J Clin Psychiatr 60:559.
12. Faries D, Herrera J, Rayamajhi J, DeBrota D, Demitrack M, Potter WZ. 2000. The responsiveness of the Hamilton Depression Rating Scale. J Psychiatr Res 34:3-10.
13. Fava M, Davidson KG. 1996. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin N Am. 19:179-200.
14. Fava M, Uebelacker LA, Alpert JE, Nierenberg AA, Pava JA, Rosenbaum JE 1997. Major depressive subtypes and treatment response. Biol Psychiatry 42:568-576.
15. Feiger A, Kiev A, Shrivastava RK, Wisselink PG, Wilcox CS. 1996. Nefazodone versus sertraline in outpatients with major depression: Focus on efficacy, tolerability, and effects on sexual function and satisfaction. J Clin Psychiatry 57:53-62.
16. Germine M, Goddard AW, Sholomskas DE, Woods SW, Charney DS, Heninger GR. 1994. Response to meta-chlorophenylpiperazine in panic disorder patients and healthy subjects: influence of reduction in intravenous dosage. Psychiatry Res 54:115-133.
17. Gillin JC, Rapaport M, Erman MK, Winokur A, Albala BJ. 1997. A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician-rated measures of sleep in depressed patients: A double-blind, 8-week clinical trial. J Clin Psychiatry 58:185-192.
18. Graeff FG, Guimaraes FS, De Andrade TG, Deakin JF. 1996. Role of 5-HT in stress, anxiety, and depression. Pharmacol Biochem Behav 54:129-141.
19. Greene DS, Barbhaiya RH. Clinical pharmacokinetics of nefazodone. Clin Pharmacokinet. 1997, 33:260-275.
20. Guy W, editor. 1976. ECDEU Assessment manual for psychopharmacology, revised. DHEW Pub. No. (ADM) 76-338. Rockville, MD: National Institute of Mental Health.
21. Haddad P. 1997. Newer antidepressants and the discontinuation syndrome. J Clin Psychiatry 58:17-22.
22. Iqbal, N, Asnis, GM, Wetzler, S, Kahn, RS, Kay, SR, van Praag, HM. 1991. The MCPP challenge test in schizophrenia: Hormonal and behavioral responses. Biol Psychiatry 30:770-778.
23. John L, Perreault MM, Tao T, Blew PG. 1997. Serotonin syndrome associated with nefazodone and paroxetine. Ann Emerg Med. 29:287-289.
24. Kahn RS, Asnis GM, Wetzler S, van Praag HM. 1988a. Neuroendocrine evidence for serotonin receptor hypersensitivity in panic disorder. Psychopharmacology (Berl) 96:360-364.
25. Kahn RS, Kalus O, Wetzler S, Cahn W, Asnis GM, van Praag HM. 1990a. Effects of serotonin antagonists on m-chlorophenylpiperazine-mediated responses in normal subjects. Psychiatry Res 33:189-198.
26. Kahn RS, Wetzler S, Asnis GM, Kling MA, Suckow RE, van Praag HM. 1990b. Effects of m-chlorophenylpiperazine in normal subjects: A dose-response study. Psychopharmacology (Berl) 100:339-344.
27. Kahn RS, Wetzler S, van Praag HM, Asnis GM, Strauman T. 1988b. Behavioral indications for serotonin receptor hypersensitivity in panic disorder. Psychiatry Res 25:101-104.
28. Lane R, Baldwin D. 1997. Selective serotonin reuptake inhibitor-induced serotonin syndrome: review. J Clin Psychopharmacol 17:208-221.
29. Lazowick AL, Levin GM. 1995. Potential withdrawal syndrome associated with SSRI discontinuation. Ann Pharmacother 29:1284-1285.
30. Lemberger HF, Mason N, Cohen ML. 1984. 5HT2 receptors in the rat portal vein: Desensitization following cumulative serotonin addition. Life Sci 35:71-77.
31. Leon AC. 1998. Descriptive and inferential statistics. In: Bellack AS, Hersen M, editors. Comprehensive clinical psychology. Oxford: Pergamon. p 243-285.
32. Mihara K, Otani K, Suzuki A, Yasui N, Nakano H, Meng X, Ohkubo T, Nagasaki T, Kaneko S, Tsuchida S, Sugawara K, Gonzalez FJ. 1997. Relationship between the CYP2D6 genotype and the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine. Psychopharmacology (Berl) 133:95-98.
33. Montgomery SA, Smeyatsky N, de Ruiter M, Montgomery DB. 1985. Profiles of antidepressant activity with the Montgomery-Asberg Depression Rating Scale. Acta Psychiatr Scand 320:38-42.
34. Nemeroff CB, DeVane CL, Pollock BG. 1996. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 153:311-320.
35. O'Sullivan RL, Fava M, Agustin C, Baer L, Rosenbaum JE 1997. Sensitivity of the six-item Hamilton Depression Rating Scale. Acta Psychiatr Scand 95:379-384.
36. Otto MW. 1992. Statistical methods for clinical psychopharmacology trials. In: Fava M, Rosenbaum J, editors. Research designs and methods in psychiatry. Amsterdam: Elsevier Science Publishers. p 247-266.
37. Richelson E. 1998. Pharmacokinetic interactions of antidepressants. J Clin Psychiatry. 59:22-26.
38. Riesenman C. 1995. Antidepressant drug interactions and the cytochrome P450 system: A critical appraisal. Pharmacotherapy 15:84S-99S.
39. Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. 1998. Selective serotonin reuptake inhibitor discontinuation syndrome: A randomized clinical trial. Biol Psychiatry 44:77-87.
40. Rotzinger S, Bourin M, Akimoto Y, Coutts RT, Baker GB. 1999. Metabolism of some "second"- and "fourth"-generation antidepressants: Iprindole, viloxazine, bupropion, mianserin, maprotiline, trazodone, nefazodone, and venlafaxine. Cell Mol Neurobiol 19:427-442.
41. Schmider J, Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI. 1996. Inhibition of cytochrome P450 by nefazodone in vitro: studies of dextromethorphan O- and N-demethylation. Br J Clin Pharmacol 41:339-343.
42. Sevy S, Brown SL, Wetzler S, Kotler M, Molcho A, Plutchik R, van Praag. HM. 1994. Effects of alprazolam on increases in hormonal and anxiety levels induced by meta-chlorophenylpiperazine. Psychiatry Res 53:219-229.
43. Silverstone PH, Cowen PJ. 1994. The 5-HT3 antagonist, BRL 46470 does not attenuate m-chlorophenylpiperazine (mCPP)-induced changes in human volunteers. Biol Psychiatry 36:309-316.
44. Singer JD, Willett JB. 1992. A practical guide to the use of survival analysis in research. In: Fava M, Rosenbaum J, editors. Research designs and methods in psychiatry. Amsterdam: Elsevier Science Publishers. p 37-83.
45. Smith RL, Barrett RJ, Sanders-Bush E. 1990. Adaptation of brain 5HT2 receptors after mianserin treatment: Receptor sensitivity, not receptor binding, more accurately correlates with behavior. J Pharmacol Exp Ther 254:484-488.
46. Sonawalla SB, Spillmann MK, Kolsky AR, Alpert JE, Nierenberg AA, Rosenbaum JF, Fava M. 1999. Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders. J Clin Psychiatry 60:580-583.
47. von Moltke LL, Greenblatt DJ, Granda BW, Grassi JM, Schmider J, Harmatz JS, Shader RI. 1999. Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: Cytochromes mediating transformation, and P450-3A4 inhibitory actions. Psychopharmacology (Berl) 145:113-122.
48. Wells KB. 1999. Treatment research at the crossroads: The scientific interface of clinical trials and effectiveness research. Am J Psychiatry 156:5-10.
49. Wetzler S, Asnis GM, DeLecuona JM, Kalus O. 1996. Serotonin function in panic disorder: Intravenous administration of metachlorophenylpiperazine. Psychiatry Res 64:77-82.
50. Zuardi AW. 1990. 5-HT-related drugs and human experimental anxiety. Neurosci Biobehav Rev 14:507-510.